Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor.

被引：0

作者：

Graff, Candace ^{[1
]}

Schwartz, Annette ^{[1
]}

Voss, Jeffrey ^{[2
]}

Wishart, Neil ^{[2
]}

Olson, Lisa ^{[1
]}

George, Jonathon ^{[2
]}

Hyland, Deborah ^{[2
]}

Camp, Heidi ^{[3
]}

机构：

[1] AbbVie Inc, AbbVie Biores Ctr, Worcester, MA USA

[2] AbbVie Pharmaceut, Worcester, MA USA

[3] Abbvie, Winnetka, IL USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1499

引用

页码：S659 / S660

页数：2

共 50 条

[1] In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier J.M.
Voss J.
Graff C.
Schwartz A.
Argiriadi M.
Friedman M.
Camp H.S.
Padley R.J.
George J.S.
Hyland D.
Rosebraugh M.
Wishart N.
Olson L.
Long A.J.
BMC Rheumatology, 2 (1)
[2] PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE SELECTIVE JAK1 INHIBITOR, ABT-494, IN HEALTHY VOLUNTEERS AND SUBJECTS WITH RHEUMATOID ARTHRITIS
Mohamed, M. -E.
Camp, H.
Jiang, P.
Padley, R.
Asatryan, A.
Othman, A. A.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 258 - 258
[3] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Genovese, M. C.
Smolen, J. S.
Weinblatt, M. E.
Meerwein, S.
Camp, H. S.
Wang, L.
Othman, A. A.
Khan, N.
Jungerwirth, S.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 141 - 142
[4] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed, Mohamed-Eslam F.
Camp, Heidi S.
Jiang, Ping
Padley, Robert J.
Asatryan, Armen
Othman, Ahmed A.
CLINICAL PHARMACOKINETICS, 2016, 55 (12) : 1547 - 1558
[5] Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed-Eslam F. Mohamed
Heidi S. Camp
Ping Jiang
Robert J. Padley
Armen Asatryan
Ahmed A. Othman
Clinical Pharmacokinetics, 2016, 55 : 1547 - 1558
[6] SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
Sandborn, William J.
Feagan, Brian G.
Panes, Julian
D'Haens, Geert R.
Colombel, Jean Frederic
Zhou, Qian
Huang, Bidan
Enejosa, Jeffrey V.
Pangan, Aileen L.
Lacerda, Ana P.
GASTROENTEROLOGY, 2017, 152 (05) : S1308 - S1309
[7] SAFETY AND EFFICACY OF ABT-494, A NOVEL SELECTIVE JAK1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO ANTI-TNF BIOLOGIC THERAPY
Kremer, J. M.
Keystone, E. C.
Emery, P.
Camp, H. S.
Friedman, A.
Wang, L.
Othman, A. A.
Khan, N.
Jungerwirth, S.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1038 - 1039
[8] Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Kremer, Joel M.
Keystone, Edward C.
Emery, Paul
Camp, Heidi S.
Friedman, Alan
Wang, Li
Othman, Ahmed A.
Khan, Nasser
Jungerwirth, Steven
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[9] CHANGES IN C-REACTIVE PROTEIN AND LIPID LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABT-494, A SELECTIVE JAK-1 INHIBITOR
Nurmohamed, M.
Zhang, Y.
Lin, J.
Camp, H.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 280 - 280
[10] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Genovese, Mark C.
Smolen, Josef S.
Weinblatt, Michael E.
Burmester, Gerd R.
Meerwein, Sebastian
Camp, Heidi S.
Wang, Li
Othman, Ahmed A.
Khan, Nasser
Pangan, Aileen L.
Jungerwirth, Steven
ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2857 - 2866

← 1 2 3 4 5 →